SG11201701247RA - Lyophilized formulations for factor xa antidote - Google Patents

Lyophilized formulations for factor xa antidote

Info

Publication number
SG11201701247RA
SG11201701247RA SG11201701247RA SG11201701247RA SG11201701247RA SG 11201701247R A SG11201701247R A SG 11201701247RA SG 11201701247R A SG11201701247R A SG 11201701247RA SG 11201701247R A SG11201701247R A SG 11201701247RA SG 11201701247R A SG11201701247R A SG 11201701247RA
Authority
SG
Singapore
Prior art keywords
antidote
factor
lyophilized formulations
lyophilized
formulations
Prior art date
Application number
SG11201701247RA
Other languages
English (en)
Inventor
Juan Wang
Gregory A Sacha
Phuong M Nguyen
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of SG11201701247RA publication Critical patent/SG11201701247RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21006Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201701247RA 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote SG11201701247RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462039809P 2014-08-20 2014-08-20
PCT/US2015/046173 WO2016029061A1 (en) 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote

Publications (1)

Publication Number Publication Date
SG11201701247RA true SG11201701247RA (en) 2017-03-30

Family

ID=55351266

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701247RA SG11201701247RA (en) 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote

Country Status (14)

Country Link
US (6) US20160237420A1 (cg-RX-API-DMAC7.html)
EP (2) EP3182993B1 (cg-RX-API-DMAC7.html)
JP (4) JP6742986B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250150675A (cg-RX-API-DMAC7.html)
CN (2) CN107073082B (cg-RX-API-DMAC7.html)
AU (3) AU2015305413B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961739C (cg-RX-API-DMAC7.html)
DK (1) DK3182993T3 (cg-RX-API-DMAC7.html)
EA (2) EA036091B1 (cg-RX-API-DMAC7.html)
ES (1) ES2814157T3 (cg-RX-API-DMAC7.html)
IL (2) IL250413B (cg-RX-API-DMAC7.html)
SG (1) SG11201701247RA (cg-RX-API-DMAC7.html)
WO (1) WO2016029061A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701764B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
CN116425860B (zh) * 2016-06-17 2025-03-04 阿雷克森制药公司 因子xa衍生物的制备
WO2018213151A1 (en) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Pharmaceutical formulation comprising incretin-insulin conjugates
ES2986389T3 (es) * 2018-05-21 2024-11-11 Chugai Pharmaceutical Co Ltd Formulación liofilizada sellada en un vial de vidrio
CN110760479A (zh) * 2019-05-17 2020-02-07 上海交通大学医学院附属瑞金医院 靶向血小板表达的凝血因子Xa及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177752T1 (de) 1992-12-15 1999-04-15 Corvas Int Inc Neue inhibitoren von faktor xa
ATE365052T1 (de) * 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US6586584B2 (en) * 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
EP1589949B1 (en) * 2003-01-08 2008-08-13 Novartis Vaccines and Diagnostics, Inc. Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
MX2011002316A (es) 2008-09-03 2011-05-10 Octapharma Ag Nuevas composiciones protectoras para el factor viii producido de manera recombinante.
CN102316893B (zh) * 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EP2523657A1 (en) * 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
KR102049254B1 (ko) * 2010-04-20 2019-11-28 옥타파마 아게 약학 단백질을 위한 신규한 안정화제
WO2012072824A1 (en) * 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
CN103945863A (zh) * 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
WO2013049804A1 (en) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
GB201310946D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Antidote
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형

Also Published As

Publication number Publication date
AU2015305413A1 (en) 2017-03-23
IL276960B (en) 2022-04-01
IL250413B (en) 2020-09-30
EA202091385A3 (ru) 2021-06-30
EP3182993A4 (en) 2018-01-17
US20250163399A1 (en) 2025-05-22
CN113171447B (zh) 2024-05-17
ES2814157T3 (es) 2021-03-26
US20180320160A1 (en) 2018-11-08
US20200299668A1 (en) 2020-09-24
EP3750556A1 (en) 2020-12-16
IL276960A (en) 2020-10-29
ZA201701764B (en) 2020-10-28
KR102867491B1 (ko) 2025-10-01
KR20250150675A (ko) 2025-10-20
AU2015305413B2 (en) 2020-09-24
US20200299667A1 (en) 2020-09-24
JP2017525704A (ja) 2017-09-07
IL250413A0 (en) 2017-03-30
EA036091B1 (ru) 2020-09-25
US11028382B2 (en) 2021-06-08
JP6742986B2 (ja) 2020-08-19
US20160237420A1 (en) 2016-08-18
CA2961739A1 (en) 2016-02-25
US20210284986A1 (en) 2021-09-16
JP2019206595A (ja) 2019-12-05
DK3182993T3 (da) 2020-09-21
CN113171447A (zh) 2021-07-27
CN107073082B (zh) 2021-04-30
EP3182993B1 (en) 2020-07-01
JP2023158199A (ja) 2023-10-26
JP2022003101A (ja) 2022-01-11
AU2024219698A1 (en) 2024-10-03
KR20170042776A (ko) 2017-04-19
KR20230007550A (ko) 2023-01-12
WO2016029061A1 (en) 2016-02-25
AU2020289768A1 (en) 2021-01-21
CA2961739C (en) 2024-04-30
EA201790415A1 (ru) 2017-08-31
EP3182993A1 (en) 2017-06-28
KR102482517B1 (ko) 2022-12-28
AU2020289768B2 (en) 2024-06-13
EA202091385A2 (ru) 2021-03-31
CN107073082A (zh) 2017-08-18
JP7416549B2 (ja) 2024-01-17

Similar Documents

Publication Publication Date Title
ZA201704297B (en) Pyrrolobenzodiazepine-antibody conjugates
PT3119885T (pt) Conjugados anticorpo-fynomer
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
GB2538413B (en) Blower
GB201409471D0 (en) Pharmaceutical composition
GB2530868B (en) Blower
IL276960B (en) Lyophilized formulations for factor xa antidote
IL281197B (en) Formulations of factor ix that have been lyophilized
IL249553A0 (en) Pharmaceutical preparations
EP3147504A4 (en) Blower
GB201409488D0 (en) Pharmaceutical composition
GB201419091D0 (en) Formulations
GB201409485D0 (en) Pharmaceutical composition
GB201419261D0 (en) Formulations
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
GB201515866D0 (en) Pharmaceutical compositions
PT3089740T (pt) Composição farmacêutica
SG10201504332VA (en) Pharmaceutical Composition
HK1240083B (en) Lyophilized formulations for factor xa antidote
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
GB201420910D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201406718D0 (en) Pyrrolobenzodiazepine-antibody conjugates